What is it about?
This review highlights what is known and current gaps in how glucagon, GLP-1, GLP-2, and GIP, act on blood vessels, with a focus on known receptors, mechanisms, molecular and cellular biology, physiology, and both pre-clinical and human studies
Featured Image
Why is it important?
There is translational interest in how this peptide family, and drugs based on their mechanisms of action (GLP-1, GLP-2, glucagon, dipeptidyl peptidase-4) control blood vessel function in health and disease (diabetes, obesity, heart disease, intestinal disorders)
Perspectives
Daniel Drucker provides broad perspectives on this topic at www.glucagon.com and @DanielJDrucker
Daniel Drucker
Lunenfeld-Tanenbaum Research Institute
Read the Original
This page is a summary of: Vascular Biology of Glucagon Receptor Superfamily Peptides: Mechanistic and Clinical Relevance, Endocrine Reviews, December 2016, Endocrine Society,
DOI: 10.1210/er.2016-1078.
You can read the full text:
Resources
Contributors
The following have contributed to this page
